Oncoinvent ASA (0RU5) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

So I'll do this in English. I'm Martin Olin, the CEO of Birkenau. Welcome to the second quarter 2024 presentation. And for those who have not heard about Birkenbauer before, we're all about Axel inhibition. And why are we doing that? We're doing that because it's known that Axel, which is a cell surface receptor or protein, is involved and critical in a number of serious diseases. I'm happy to report that on our very focused strategy, we progressed very well in the second quarter. particularly on the clinical and on the financial aspects. In our main study, which is called BGBC16, which is a study in frontline therapy in non-small cell lung cancer for patients who have a mutation in a gene called STK11, a significant unmet medical need. I'm happy to report that we have completed all the three cohorts in the phase 1B. So the 1B is a safety study. We tested three doses, 75, 100, and 150 milligrams. And we received a positive recommendation for the Data Safety Monitoring Board, allowing us to include the second dose of two doses in the 2A part, which is specifically for patients who have the STK11 mutation. So that's ongoing, and that's a great achievement for the company. The study is designed to involve up to 40 patients in the Phase 2A part. Of course, a Phase 2A study is not a randomized study, so there is per se no control arm. That's quite usual for a Phase IIa study, but we have addressed The need, I would say, for having a reference instead of a control arm. So we have teamed up with Tempus, one of the leaders within artificial intelligence for what is called tumor ctDNA profiling, which means gene profiling of the patients, a US company listed on NASDAQ that has a unique network to a number of hospitals in the US. And I'll come back to what this means for the s...